Request Demo
Plus Therapeutics to Present at Gordon Research Conference on Radionuclide Theranostics for Cancer
15 July 2024
On July 2, 2024, Plus Therapeutics Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical firm specializing in targeted radiotherapeutics for central nervous system (CNS) cancers, made a significant announcement from its Austin, Texas headquarters. Dr. Melissa Moore, the company’s Vice President of Clinical Research and Development, is set to deliver a presentation at the prestigious Gordon Research Conference on Radionuclide Theranostics for Cancer Management. The conference will be held on July 8, 2024, in Newry, Maine, and Dr. Moore's session is scheduled for 11:30 a.m. EDT.
Dr. Moore’s presentation will focus on data from the ongoing ReSPECT-GBM and ReSPECT-LM clinical trials. These studies are evaluating the efficacy of Plus Therapeutics' leading radiotherapeutic candidate, rhenium (186Re) obisbemeda, in treating recurrent glioblastoma (GBM) and leptomeningeal metastases (LM).
The title of Dr. Moore's talk is "Targeted Radiolabeled Nanoliposomes for Rare CNS Cancers: An Update on the ReSPECT Phase 1/2 Trials." It will be part of the conference session dedicated to updates on clinical trials in radionuclide theranostics.
Plus Therapeutics is focused on developing advanced therapeutic solutions for challenging CNS cancers. The company’s approach integrates image-guided beta radiation with targeted drug delivery systems, aiming to improve patient outcomes significantly. The pipeline of product candidates is particularly concentrated on recurrent GBM and LM, both of which are notoriously difficult to treat.
The company has established a robust supply chain through strategic collaborations that support the development, manufacturing, and potential future commercialization of its therapeutic products. Plus Therapeutics operates from key cancer clinical development hubs in Austin and San Antonio, Texas. The leadership team is comprised of seasoned professionals dedicated to advancing the field of targeted radiotherapeutics for CNS cancers.
In summary, Plus Therapeutics continues to make strides in the field of targeted radiotherapeutics, fostering hope for improved treatments for patients with challenging CNS cancers. Dr. Moore’s upcoming presentation at the Gordon Research Conference is anticipated to provide valuable insights into the company's latest clinical trial findings and future directions.
Dr. Moore’s presentation will focus on data from the ongoing ReSPECT-GBM and ReSPECT-LM clinical trials. These studies are evaluating the efficacy of Plus Therapeutics' leading radiotherapeutic candidate, rhenium (186Re) obisbemeda, in treating recurrent glioblastoma (GBM) and leptomeningeal metastases (LM).
The title of Dr. Moore's talk is "Targeted Radiolabeled Nanoliposomes for Rare CNS Cancers: An Update on the ReSPECT Phase 1/2 Trials." It will be part of the conference session dedicated to updates on clinical trials in radionuclide theranostics.
Plus Therapeutics is focused on developing advanced therapeutic solutions for challenging CNS cancers. The company’s approach integrates image-guided beta radiation with targeted drug delivery systems, aiming to improve patient outcomes significantly. The pipeline of product candidates is particularly concentrated on recurrent GBM and LM, both of which are notoriously difficult to treat.
The company has established a robust supply chain through strategic collaborations that support the development, manufacturing, and potential future commercialization of its therapeutic products. Plus Therapeutics operates from key cancer clinical development hubs in Austin and San Antonio, Texas. The leadership team is comprised of seasoned professionals dedicated to advancing the field of targeted radiotherapeutics for CNS cancers.
In summary, Plus Therapeutics continues to make strides in the field of targeted radiotherapeutics, fostering hope for improved treatments for patients with challenging CNS cancers. Dr. Moore’s upcoming presentation at the Gordon Research Conference is anticipated to provide valuable insights into the company's latest clinical trial findings and future directions.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.